Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 313

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 313
---
                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 101.SCH | XBRL Taxonomy Extension Schema.                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase.                                                                                                                                                                                                                                                                                                                                                                                                    |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase.                                                                                                                                                                                                                                                                                                                                                                                                     |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase.                                                                                                                                                                                                                                                                                                                                                                                                          |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase.                                                                                                                                                                                                                                                                                                                                                                                                   |
| 104.1   | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).                                                                                                                                                                                                                                                                                                                                                        |

| 186 | SANOFIFORM 20-F2024 |

| Signatures |

Signature The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

| Sanofi |                         |
| By:    | /s/ PAUL HUDSON         |
| Name:  | Paul Hudson             |
| Title: | Chief Executive Officer |

Date: February 13, 2025

| SANOFIFORM 20-F2024 | 187 |

| 2024CONSOLIDATED FINANCIAL STATEMENTS                    |
| Report of Independent Registered Public Accounting Firms |

Report of Independent Registered Public Accounting Firms To the Shareholders and the Board of Directors of Sanofi, Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of Sanofi and its subsidiaries (the “Company”) as of December 31, 2024, and the related consolidated income statement, and consolidated statements of comprehensive income, of changes in equity and of cash flows for the year then ended December 31, 2024, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year then ended, in conformity with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board and in conformity with IFRS as endorsed by the European Union. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2024, based